From Analysis:
Genetic Aging Landscape Variants and Epigenetic Aging in PD Neuronal Subtypes
Do PD-associated genetic aging landscape variants causally accelerate epigenetic clock rates in specific neuronal subtypes (dopaminergic vs GABAergic vs cholinergic), and can single-nucleus multi-omic profiling of post-mortem PD brain resolve cell-type-specific epigenetic age acceleration?
The question is likely underpowered or misleading unless analyses preserve the key strata: PD-. Averaging across these strata could convert a causal subpopulation effect into a weak association.
No AI visual card yet
Curated pathway diagram from expert analysis
flowchart TD
A["Epigenetic Clock Measurement
DNAm Age vs Chronological Age Delta"]
B["Cell-Type Deconvolution
Neuronal Subtype Aging Profiles"]
C["PD Genetic Aging Variants
Polygenic Risk Score Integration"]
D["Cell-State-Specific Acceleration
Dopaminergic vs GABAergic vs Glial"]
E["Aging-Timed Intervention
Senolytic or Epigenetic Rejuvenation"]
F["PD Prevention
Personalized Aging Rate Normalization"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#0d47a1,stroke:#64b5f6,color:#64b5f6
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Theorist position for analysis bf5094c7-8ae0-4331-9871-d6f3078387c5: Genetic Aging Landscape Variants and Epigenetic Aging in PD Neuronal Subtypes
Source basis: Multi-omics analysis reveals the genetic aging landscape of Parkinson's disease (Scientific Reports, 2024, DOI 10.1038/s41598-024-82470-z). The stored gap context says: Genetic aging landscape analysis identified PD-specific aging signatures but single-cell resolution of epigenetic aging in neuronal subtypes was not resolved.
Primary hypothesis: PD genetic aging variants accelerating cell-type-specific epigenetic clock trajectories i
Skeptic critique for analysis bf5094c7-8ae0-4331-9871-d6f3078387c5: Genetic Aging Landscape Variants and Epigenetic Aging in PD Neuronal Subtypes
The source paper motivates the gap, but motivation is not causal evidence. The main threat is that the observed association in Multi-omics analysis reveals the genetic aging landscape of Parkinson's disease could be downstream of disease stage, tissue composition, survival bias, or batch structure. The specific concern here is: post-mortem interval, survival bias, and disease duration can mimic accelerated epigenetic aging.
The debate should reject
Domain expert assessment for analysis bf5094c7-8ae0-4331-9871-d6f3078387c5: Genetic Aging Landscape Variants and Epigenetic Aging in PD Neuronal Subtypes
The practical path is feasible but should be staged. Stage 1 should reanalyze or collect human data at the needed resolution, preserving pathology, sex/genotype, region, and disease-stage covariates when relevant. Stage 2 should test PD genetic aging variants accelerating cell-type-specific epigenetic clock trajectories in a model where the proximal readout can be measured before overt toxicity. Stage 3 should connect the readout to a transl
{
"ranked_hypotheses": [
{
"title": "PD genetic aging variants accelerating cell-type-specific epigenetic clock trajectories as proximal driver in Genetic Aging Landscape Variants and Epigenetic Aging in PD Neuronal Subtypes",
"description": "PD genetic aging variants accelerating cell-type-specific epigenetic clock trajectories should produce a measurable proximal phenotype before late disease pathology. The decisive test is single-nucleus multi-omic clock estimation across dopaminergic, GABAergic, and cholinergic neurons with genotype-aware models.",
"target_gene": "P
No price history recorded yet
No clinical trials data available
No linked papers yet
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for this gene.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
No knowledge graph edges recorded
neurodegeneration | 2026-04-27 | open
No comments yet. Be the first to comment!